Search

everythinglearnresearchcommunity

for

Search:↓

Botulinum toxin shows promise for various skin conditions but requires more research for confirmation and standardized use.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

SSRIs may help manage sexual behavior in dementia patients, but they can cause long-lasting sexual dysfunction.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Effective treatments for discoid lupus erythematosus are needed, as current options are unsatisfactory and off-label.

Many treatments for hair loss show potential, but more testing is needed to confirm their effectiveness. Only minoxidil for women and minoxidil and finasteride for men are FDA approved.

The conclusion is that effectively treating hair disorders is difficult due to the complex factors affecting hair growth and more research is needed to improve treatments.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

Hormone treatments can help with women's skin and hair disorders, but they need careful monitoring and more research.

Taking spironolactone doesn't increase the chance of breast cancer coming back.

H-1 antihistamines may help with various skin conditions, but more research is needed to confirm their effectiveness.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.

Ketoconazole cream is effective for skin conditions like seborrheic dermatitis and may help with hair loss and other skin issues, with generally mild side effects.

Finasteride and minoxidil are effective FDA-approved treatments for androgenetic alopecia.

Testosterone therapy can improve sexual desire and function in postmenopausal women but should be used cautiously and not based solely on testosterone levels.

Many treatments for hair loss lack proper testing and FDA approval, so their effectiveness is uncertain.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

Most American men experience hair loss by age 50, with limited effective treatments available and new options not expected soon.

The conclusion is that off-label drug use can lead to important medical discoveries and improve patient care.

Minoxidil helps treat eyebrow thinning, monilethrix, early hair loss, and shortens chemo-related hair loss.

The document concludes that doctors should carefully consider off-label drug use in dermatology and always inform patients, while more research is needed on the safety and effectiveness of such practices.

Off-label drug use can be risky but sometimes beneficial when standard treatments fail.

Topical vitamin D is useful for some skin conditions but not effective for others, and more research is needed.

Clinicians should use social and prescription data to track trends in performance-enhancing drug use.

Photobiomodulation therapy may help treat hair loss in people with darker skin, but more research is needed.

Ageratum conyzoides L. extract may effectively and safely treat hair loss.

Botulinum toxins effectively treat excessive sweating and may help with other skin conditions, but more research is needed.

Latisse (bimatoprost 0.03%) is widely used in dermatology but the document doesn't give detailed evidence or numbers.

PRP and PRF show promise for hair growth but need more research for consistent and safe use.